CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 36 enrolled
Drug / intervention
Riluzoledrug
Likely dose
Riluzole 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00876889
NCT00876889N/ACompleted
CompareCT.gov

Safety and Pharmacokinetics of Riluzole in Patients With Traumatic Acute Spinal Cord Injury

The Methodist Hospital Research Institute·observational·Posted Apr 7, 2009·Updated Sep 12, 2017

In Brief

An observational study evaluating Riluzole for Spinal Cord Injury. Completed, enrolled 36 participants across 8 sites in 2 countries.

Detailed Summary

The purpose of the study is to find out if the use of the drug Riluzole is both safe and improves outcome in patients with acute traumatic spinal cord injury (SCI).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injury
CountriesCanada, United States
CollaboratorsChristopher Reeve Paralysis Foundation, United States Department of Defense, AO Clinical Investigation and Publishing Documentation, Ontario Neurotrauma Foundation

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 7, 2009
Enrollment StartApr 1, 2010
Primary CompletionJun 1, 2011
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 17.2 years ago

Interventions

Riluzoledrug

50mg PO (by mouth) every 12 hours starting within 12 hours of injury and continuing for 14 days (28 doses).